Jun 15
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are still asked to provide it.
Read the full article featuring Janice Chang from STAT here.
Related Blog Posts
Why 2026 could be a turning point for patient-focused trials
The clinical research ecosystem has spent more than a decade saying the right things about patient engagement. Health authorities, patient groups, sponsors, academic institutions, and a host of life science companies have all committed — publicly and repeatedly — to making it a priority. And yet the collective efforts across these stakeholders have remained fragmented.…
What happens when protocol data finally flows
Clinical research has no shortage of technology. What it lacks is the ability to scale in ways that allow information to flow automatically across systems and support digitally enabled workflows for critical stakeholders. Read the full article featuring Rob DiCicco from Clinical Trials Arena here.
FDA Conversation on Selective Safety Data Collection
Earlier this month, TransCelerate BioPharma released a summary report focused on selective safety data collection (SSDC) gathered during a joint tabletop exercise convened in late 2025 in collaboration with U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI). Read the full article from Clinical Research…